December 10-13, 2022; New Orleans, Louisiana
In a nonrandomized cohort analysis of adult patients with high-risk BCP-ALL, those who received blinatumomab during consolidation had improved clinical outcomes, including a higher MRD rate, lower incidence of relapse, and longer disease-free survival.